RU2007112117A - Вакцинная композиция против вируса гепатита с - Google Patents
Вакцинная композиция против вируса гепатита с Download PDFInfo
- Publication number
- RU2007112117A RU2007112117A RU2007112117/13A RU2007112117A RU2007112117A RU 2007112117 A RU2007112117 A RU 2007112117A RU 2007112117/13 A RU2007112117/13 A RU 2007112117/13A RU 2007112117 A RU2007112117 A RU 2007112117A RU 2007112117 A RU2007112117 A RU 2007112117A
- Authority
- RU
- Russia
- Prior art keywords
- vaccine composition
- antigens
- composition according
- virus
- hepatitis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (13)
1. Вакцинная композиция для создания защитного клеточного и гуморального иммунного ответа против вируса гепатита С, характеризующаяся оптимальной комбинацией структурных антигенов вируса гепатита С (ядерный, Е1 и Е2), и вводимая с использованием адъюванта любого типа.
2. Вакцинная композиция по п.1, где количество используемых антигенов находится в интервале соотношений [(1.5-2.5):(1-2.5):(1-2)]:[ядерный:E1:E2], для создания оптимального гуморального иммунного ответа.
3. Вакцинная композиция по п.2, где количество используемых антигенов представляет собой соотношение (1,5:1,1:1):(ядерный:E1:E2).
4. Вакцинная композиция по п.1, где количество используемых антигенов находится в интервале соотношений [(1:50):(120-180):(120-180)]:[ядерный:E1:E2], для создания оптимального клеточного иммунного ответа.
5. Вакцинная композиция по п.4, где количество используемых антигенов представляет собой соотношение (1:160:160):(ядерный:E1:E2).
6. Вакцинная композиция по любому из пп. 1-5, которая вводится согласно различным схемам иммунизации.
7. Комбинированные вакцинные композиции против вирусных и/или бактериальных заболеваний, где смесь структурных антигенов вируса гепатита С в качестве активных компонентов объединена, в соответствии с пп. 1-5, с полисахаридами (конъюгированными или неконъюгированными) и/или вирусными, и/или бактериальными антигенами.
8. Комбинированная вакцинная композиция против вирусных и/или бактериальных заболеваний, где смесь структурных антигенов вируса гепатита С в качестве активных компонентов объединена, в соответствии с пп. 1-5, с плазмидами, кодирующими антигены инфекционных агентов.
9. Комбинированная вакцинная композиция по п.7, где используемыми вирусными антигенами являются ядерный и/или поверхностный антиген вируса гепатита В.
10. Комбинированная вакцинная композиция по п.7, где используемыми бактериальными антигенами являются белки наружной мембраны N. meningitidis, отдельно или в составе вакцинной композиции.
11. Комбинированная вакцинная композиция по п.7, где полисахаридные антигены, конъюгированные или неконъюгированные с белками-носителями, используются в качестве активных компонентов в составах против бактериальных агентов.
12. Вакцинная композиция по любому из пп. 1-5, которая вводится согласно комбинированным схемам с другими кандидатными вакцинами на основе ДНК конструкций, живых вирусных векторов, пептидов и белков.
13. Вакцинная композиция по любому из пп. 1-5 для индукции иммунного ответа против вируса гепатита С у пациентов, страдающих хроническим гепатитом С, циррозом и раком печени.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU2004-0189 | 2004-09-03 | ||
CU20040189A CU23496A1 (es) | 2004-09-03 | 2004-09-03 | Composición vacunal contra el virus de la hepatitis c |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2007112117A true RU2007112117A (ru) | 2008-10-10 |
RU2351363C2 RU2351363C2 (ru) | 2009-04-10 |
Family
ID=40262832
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2007112117A RU2351363C2 (ru) | 2004-09-03 | 2005-08-29 | Вакцинная композиция против вируса гепатита с |
Country Status (15)
Country | Link |
---|---|
US (1) | US20080138360A1 (ru) |
EP (1) | EP1785143B1 (ru) |
JP (1) | JP4917539B2 (ru) |
KR (1) | KR101245154B1 (ru) |
CN (1) | CN101043902B (ru) |
AR (1) | AR052639A1 (ru) |
AU (1) | AU2005279590B2 (ru) |
BR (1) | BRPI0514884A (ru) |
CA (1) | CA2577918C (ru) |
CU (1) | CU23496A1 (ru) |
HK (1) | HK1109069A1 (ru) |
MX (1) | MX2007002659A (ru) |
RU (1) | RU2351363C2 (ru) |
WO (1) | WO2006024240A2 (ru) |
ZA (1) | ZA200701674B (ru) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG174845A1 (en) | 2006-09-29 | 2011-10-28 | Ligocyte Pharmaceuticals Inc | Norovirus vaccine formulations |
JP2010539192A (ja) | 2007-09-18 | 2010-12-16 | リゴサイト ファーマスーティカルズ,インコーポレイテッド | ノロウイルスに対して防御免疫応答を付与する方法 |
US20100266636A1 (en) | 2007-09-18 | 2010-10-21 | Ligocyte Pharmaceuticals, Inc. | Method of conferring a protective immune response to norovirus |
KR101793161B1 (ko) * | 2008-08-08 | 2017-11-03 | 다케다 백신즈 인코포레이티드 | 강화된 교차 반응성을 가진 복합체 캡시드 아미노산 서열들을 포함하는 바이러스-유사 입자들 |
ES2656527T3 (es) | 2011-07-11 | 2018-02-27 | Takeda Vaccines, Inc. | Formulaciones parenterales de vacunas de norovirus |
RU2510998C2 (ru) * | 2012-08-01 | 2014-04-10 | Николай Николаевич Грановский | ВАКЦИНА НА ОСНОВЕ ВИРУСОПОДОБНЫХ ЧАСТИЦ, СОДЕРЖАЩИХ ВСЕ СТРУКТУРНЫЕ АНТИГЕНЫ ВИРУСА ГЕПАТИТА С, И СПОСОБ ЕЕ ПОЛУЧЕНИЯ В ДРОЖЖАХ Hansenula polymorpha |
CU24112B1 (es) | 2012-11-05 | 2015-08-27 | Ct De Ingeniería Genética Y Biotecnología | Antígenos vacunales quiméricos contra el virus de la hepatitis c |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7070790B1 (en) * | 1993-06-29 | 2006-07-04 | The United States Of America As Represented By The Department Of Health And Human Services | Nucleotide and deduced amino acid sequences of the envelope 1 and core genes of isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines |
NZ296304A (en) * | 1994-10-05 | 1999-06-29 | Apollon | Hepatitis c vaccine components |
AU738585B2 (en) * | 1996-11-08 | 2001-09-20 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Synthesis and purification of hepatitis C virus-like particles |
NZ518999A (en) * | 1999-11-19 | 2002-12-20 | Csl Ltd | Vaccine compositions |
WO2002038793A2 (en) * | 2000-11-07 | 2002-05-16 | Anadys Pharmaceuticals, Inc. | Hepatitis c virus constructs characterized by high efficiency replication |
US7101561B2 (en) * | 2000-12-01 | 2006-09-05 | Innogenetics N.V. | Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use |
WO2002097091A1 (en) * | 2001-05-29 | 2002-12-05 | University Of Miami | Generation of hcv-like particles and chimeric hcv virus |
CU23244A1 (es) * | 2001-07-16 | 2007-10-17 | Ct Ingenieria Genetica Biotech | Formulacion vacunal potenciada por la combinacion de un adn con un antigeno |
DE10143490C2 (de) * | 2001-09-05 | 2003-12-11 | Gsf Forschungszentrum Umwelt | Rekombinantes MVA mit der Fähigkeit zur Expression von HCV Struktur-Antigenen |
-
2004
- 2004-09-03 CU CU20040189A patent/CU23496A1/es not_active IP Right Cessation
-
2005
- 2005-08-22 AR ARP050103513 patent/AR052639A1/es not_active Application Discontinuation
- 2005-08-29 EP EP20050779477 patent/EP1785143B1/en active Active
- 2005-08-29 RU RU2007112117A patent/RU2351363C2/ru not_active IP Right Cessation
- 2005-08-29 WO PCT/CU2005/000005 patent/WO2006024240A2/es active Application Filing
- 2005-08-29 AU AU2005279590A patent/AU2005279590B2/en not_active Ceased
- 2005-08-29 CN CN2005800362181A patent/CN101043902B/zh not_active Expired - Fee Related
- 2005-08-29 CA CA 2577918 patent/CA2577918C/en not_active Expired - Fee Related
- 2005-08-29 MX MX2007002659A patent/MX2007002659A/es active IP Right Grant
- 2005-08-29 BR BRPI0514884-7A patent/BRPI0514884A/pt not_active IP Right Cessation
- 2005-08-29 JP JP2007528569A patent/JP4917539B2/ja not_active Expired - Fee Related
- 2005-08-29 KR KR1020077006792A patent/KR101245154B1/ko not_active IP Right Cessation
- 2005-08-29 US US11/661,217 patent/US20080138360A1/en not_active Abandoned
-
2007
- 2007-02-26 ZA ZA200701674A patent/ZA200701674B/xx unknown
- 2007-12-31 HK HK07114321A patent/HK1109069A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
KR101245154B1 (ko) | 2013-03-19 |
EP1785143A2 (en) | 2007-05-16 |
CA2577918A1 (en) | 2006-03-09 |
AU2005279590A1 (en) | 2006-03-09 |
WO2006024240A3 (es) | 2006-06-01 |
CA2577918C (en) | 2013-05-28 |
JP2008511556A (ja) | 2008-04-17 |
KR20070057861A (ko) | 2007-06-07 |
RU2351363C2 (ru) | 2009-04-10 |
BRPI0514884A (pt) | 2008-06-24 |
MX2007002659A (es) | 2007-05-16 |
HK1109069A1 (en) | 2008-05-30 |
EP1785143B1 (en) | 2015-03-04 |
JP4917539B2 (ja) | 2012-04-18 |
AR052639A1 (es) | 2007-03-28 |
CU23496A1 (es) | 2010-02-23 |
CN101043902A (zh) | 2007-09-26 |
WO2006024240A2 (es) | 2006-03-09 |
ZA200701674B (en) | 2008-08-27 |
US20080138360A1 (en) | 2008-06-12 |
CN101043902B (zh) | 2012-04-18 |
AU2005279590B2 (en) | 2010-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2007112117A (ru) | Вакцинная композиция против вируса гепатита с | |
KR100900837B1 (ko) | 리포펩타이드와 폴리(i:c)를 아쥬반트로 포함하는 강력한백신 조성물 | |
EA200100619A1 (ru) | Коровые антигенные частицы hbv с множественными иммуногенными компонентами, связанными посредством пептидных лигандов | |
Chua et al. | Hepatitis C VLPs delivered to dendritic cells by a TLR2 targeting lipopeptide results in enhanced antibody and cell-mediated responses | |
ATE331530T1 (de) | Proteasom-influenzavirus-impfstoffzusammensetzu g | |
RU2007127993A (ru) | Сахарид-конъюгатные вакцины | |
JP2009501901A5 (ru) | ||
DE69111801D1 (de) | Vakzin gegen hepatitis b. | |
WO2001095919A3 (en) | A recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses | |
DK1443960T3 (da) | Antigen-arrays der betegner IL-5, IL-13 eller eotaxin til behandling af allergiske eosinofile sygdomme | |
JP2006504644A5 (ru) | ||
RU2012140741A (ru) | Композиции рекомбинантного cdv и ее применение | |
RU2017129340A (ru) | Композиции nеisseria мeningitidis и способы их получения | |
JP2009522368A5 (ru) | ||
JP2002534481A5 (ru) | ||
CA2360382A1 (en) | Use of antibodies for the vaccination against cancer | |
US8691234B2 (en) | Vaccine formulation potentiated by the combination of DNA and an antigen | |
ES2564183T3 (es) | Adyuvantes de vacuna | |
RU2313363C2 (ru) | Очищенные белки оболочки вируса гепатита с для диагностического и терапевтического применения | |
WO2001083528A3 (en) | Nucleic acid immunization | |
CN103435690B (zh) | 一种丙型肝炎病毒的dna疫苗及其制备方法 | |
GB9925966D0 (en) | Threapeutic vaccines against variable viruses and other targets | |
RU2003117058A (ru) | Вирусные вакцины | |
TW200540188A (en) | Peptide capable of combining with human tissue antigen and its amino acid sequence | |
Javadi et al. | Synthesis and characterization of physicochemical and immunological properties of recombinant NS3-G2 dendrimer conjugate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20160830 |